Hosted on MSN
The secret life of ALAS1: Basic science discovery could the pave way for better small interfering RNA therapies
In everyday life, when things turn out the opposite of what you expect, it's usually a cause for frustration. In science, it's often the starting point for discovery. That's what happened to a team of ...
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and ...
(A and B) Preparation process of the self-assembly of peptide, DNR prodrug, and siRNA, along with the corresponding formulation ratios. (C) DLS detection of the particle size of PDR at different ...
CHICAGO -- Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results